Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.
RAMP1 acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL and transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. For a ...